Target intelligence / Profile preview

Cardiomyocyte Maturation Associated long non-coding RNA (CARMA)

Target
CARMA
Molecular classification
Other, Long non-coding RNA (lncRNA)
01

Overview

Cardiomyocyte Maturation Associated lncRNA (CARMA) is a conserved long non-coding RNA located adjacent to MIR-1-1HG, the host gene for key cardiogenic microRNAs MIR1-1 and MIR-133a2. CARMA is transcribed antisense to these microRNAs and negatively regulates their expression. Knockdown of CARMA leads to increased expression of these microRNAs and further coordinate downregulation of their protein-coding targets, including RBPJ, a central effector in the NOTCH signaling pathway critical for cardiac development. CARMA thus forms part of a regulatory network involving lncRNAs, myomirs, and NOTCH pathway components, orchestrating the balance of differentiation and maturation in human pluripotent stem cell-derived cardiomyocytes[1]. Its function is critical for the specification of cardiac lineage and inhibition of neuroectodermal specification, but there is no evidence it acts as a classical therapeutic target such as a receptor, enzyme, or transporter[1][2].

Other names
CRMAFLJ30313CARDIOMYOCYTE MATURATION-ASSOCIATED lncRNAC20orf200NCRNA00335C20orf166-AS1MIR1-1HG-AS1Non-Protein Coding RNA 335Chromosome 20 Open Reading Frame 200C20orf166 Antisense RNA 1
02

Mechanism of action

not applicable (no known drugs or therapeutics target CARMA directly)

03

Biological functions

Cardiomyocyte differentiationCardiomyocyte maturationRegulation of microRNA expressionControl of cell fate between mesoderm and neuroectoderm lineagesRegulation of NOTCH signaling pathway
04

Disease associations

Cardiovascular disease (by affecting cardiogenesis and thereby the potential development of heart conditions)Potential roles in congenital heart defects and cardiomyopathies (speculative, based on function)
05

Safety considerations

none reported; not a drug target, so safety concerns pertain only to experimental manipulation (e.g., knockdown/overexpression affecting cardiac development)[1]
06

Biomarkers

none established; possible experimental marker for cardiomyocyte maturation in stem cell differentiation protocols, but not used clinically[1]

Beyond the preview

Go deeper on Cardiomyocyte Maturation Associated long non-coding RNA (CARMA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardiomyocyte Maturation Associated long non-coding RNA (CARMA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call